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The Immune Microenvironment of Microsatellite Instable Endometrial
Cancer
Janelle Beth Pakish, M.D., M.S.
Advisory Professor: Karen Lu, M.D.
Limited treatment options are available for patients with advanced and recurrent
endometrial cancer (EC) should standard chemotherapy fail. Recent studies in other
tumor types have shown that tumors with high microsatellite instability (MSI-H) have
increased immunogenicity and response to immunotherapy treatments compared to
microsatellite stable (MSS) tumors. Patients with MSI-H EC may also benefit from these
therapies; however, the tumor immune microenvironment in MSI-H EC has not yet been
well described.
In order to evaluate the immune microenvironment of MSI-H EC, multiple
approaches were used, including analysis of large publically available datasets and
detailed characterization of patient tumor samples. Uterine cancer data from The Cancer
Genome Atlas (TCGA) was used to study immune-related gene expression in MSI-H EC
compared to MSS EC at both the individual gene and pathway level. Fluorescent
multiplexing immunohistochemistry (IHC) was used to evaluate differences in immune
cell populations using tumor specimens from these two groups followed by automated
multispectral imaging and analysis to visualize and quantify staining in the tumor
epithelial and stromal compartments. Nonparametric Mann-Whitney test was used to
determine statistical significance (p value <0.05) of positive cell counts for CD3, CD4,
CD8, CD103, CD68, CD11c, granzyme B, and PD-L1 between the groups.
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Overall, MSI-H EC demonstrated increased immune activation compared to MSS
EC. Using TCGA data, MSI-H (n=118) EC showed overall activation of the granzyme B
signaling pathway compared to MSS (n=160) EC (p <0.01). IHC analysis demonstrated
increased granzyme B+ cells (114.9 cells/mm2 vs 75.8 cells/mm2; p<0.01), activated
cytotoxic T cells (CTLs) (45.6 cells/mm2 vs 28.0 cells/mm2; p<0.01), and PD-L1+ cells
(291.6 cells/mm2 vs 240.5 cells/mm2; p<0.01) in the stroma of MSI-H versus MSS ECs.
The number of granzyme B+ and activated cytotoxic T cells was also increased in the
tumor epithelial compartment of MSI-H compared to MSS ECs. There was no difference
in the other markers evaluated.
In conclusion, the immune microenvironment differs in MSI-H ECs with
increased tumor immunogenicity compared to MSS tumors. Elevated PD-L1 expression
also suggests immune response inhibition in these tumors, and patients with this subset of
tumors are likely candidates for immune checkpoint blocking agents.
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Chapter 1: Introduction
OVERVIEW
As the most frequent gynecologic malignancy in the Unites States, endometrial
cancer (EC) is predicted to affect approximately 60,000 women in 2016 with a subsequent
10,500 EC related deaths (1). Due to the presence of early warning symptoms, such as
postmenopausal bleeding, the majority of women with EC are diagnosed at an early stage
(70%). Disease is typically localized to the uterus and has an associated 5-year overall
survival (OS) of nearly 95% (2). In fact, most women with early stage disease are cured
with hysterectomy alone (2). While the initial prognosis is positive, a subset of these
patients will recur. Additionally, those women who have recurrent disease, or who are
found to have advanced stage, have a worse prognosis with 5-year OS ranging from only
20-66% (3). Given the poor outcomes for recurrent and advanced disease, it is critical to
identify key molecular subtypes amenable to targeted therapeutic strategies and to identify
sub-groups that are more likely to recur.
Many factors are known to increase the risk of EC. Primarily, these risk factors
include those that increase estrogen exposure like estrogen only hormone replacement
therapy, obesity, early menarche, and late menopause. Inherited genetic syndromes, such
as Lynch syndrome (LS), can also lead to increased risk of endometrial cancer. LS is an
autosomal dominantly inherited disorder of a germline mutation in a DNA mismatch repair
(MMR) gene that cause DNA MMR deficiency. These DNA MMR deficiency genes
include: MLH1 (human mutL homolog 1), MSH2 (human mutS homolog 2), MSH6 (human
mutS homolog 6), PMS2 (human postmeitotic segregation 2), and EPCAM (epithelial cell
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adhesion molecule). Secondary to MMR deficiency, LS is associated with an elevated
risk of developing EC, as well as, colorectal, ovarian, stomach, renal, ureteral, biliary tract,
and central nervous system cancers (4). The lifetime risk of EC in women with LS is 60%,
and about half will present with EC or ovarian cancer as their initial cancer diagnosis (4,
5). The specific risk of EC with MSH6 mutations is 73%, 31% with MLH1, and 29% with
MSH2 (6), and more than 80% of LS-related ECs demonstrate endometrioid histology (4).
Overall, EC includes a wide spectrum of clinical, pathological, and molecular
features that have been used to classify EC into different subtypes. Traditionally this
included subdivision of EC into two categories (7). Type 1 tumors are the most common
and consist mostly of the early stage and good prognosis cases described earlier. These
tumors are also typically estrogen-dependent, of endometrioid histology, and low grade.
Type 2 tumors, on the other hand, tend to be more aggressive, are of non-endometrioid
histology, and have an overall worse prognosis. The Cancer Genome Atlas (TCGA) for
uterine cancer created an integrated genomic characterization to provide a more
sophisticated view of EC subtypes. The initial analysis of uterine cancer TCGA data
included all tumors (multiple histologic subtypes together) and identified four unique
groups characterized by somatic nucleotide substitutions (8). These groups included an
ultramutated group of polymerase ε (POLE) mutations, a hypermutated group containing
tumors with microsatellite instability (MSI), a low mutational rate group (copy-number
low), and a copy-number high group comprising mostly non-endometrioid histology
tumors. Later studies were conducted to characterize the molecular mechanisms underlying
the observed clinical heterogeneity and identify subtypes at higher risk of recurrence. Liu
et al. utilized the TCGA uterine data along with a separate validation tumor sample set to
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perform molecular subtyping of endometrioid EC (9). In this analysis, they found four
discreet subtypes of endometrioid EC that were defined by clinical, pathological, and
mutational patterns. Cluster I consisted of tumors with low grade and stage along with
increased expression of estrogen and progesterone receptors. Cluster II also contained low
grade and stage tumors, but demonstrated worse survival and significantly more betacatenin (CTNNB1) mutations. Cluster III and IV on the other hand, contained more
advanced stage and advanced grade tumors, as well as, more P53 mutations. Myosin 1
(MYH1) and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations were also
more frequently seen in Cluster III, and cytokine IK (IK) mutations were limited to Cluster
IV. MSI was seen in all clusters, but represented half of cases in both Cluster III and IV
and Lynch-related cases were not specifically examined. The different mutational profiles
of these four clusters are demonstrated in Figure 1. Although our understanding of EC
biology has advanced with these molecular classifications, these molecular fingerprints
have not yet been translated to success using current targeted agents.
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Figure 1. TCGA uterine cancer clusters by gene expression.
Distinct gene expression profiles are seen among the four endometrioid endometrial
cancer subtypes. Red signifies normalized mRNA expression levels greater than the mean
and green indicates those below the mean. Reproduced with permission from Oxford
University Press: Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati r,
Mardis ER, Levine DA, Shmulevich I, Broaddus RR, Zhang W, Clinical Significance of
CTNNB1 Mutation and WnT Pathway Activation in Endometrioid Endometrial
Carcinoma. J Natl Cancer Inst, 2014;106 (9).

LYNCH SYNDROME AND MICROSATELLITE INSTABILITY
One molecular subset of EC that has recently gained attention as a potential target
for specific therapeutics is defined by microsatellite instability. This group includes both
inherited LS-related and sporadic MSI EC, which both result from defects in DNA MMR.
Damage to this pathway results in deficient repair of base pair mismatches that occur
4

during DNA replication (4). This deficiency then leads to multiple errors in areas of
repetitive DNA sequences, known as microsatellites, resulting in microsatellite instability
in these tumors (4). In sporadic MSI tumors, sporadic hypermethylation of the MLH1
promoter results in MMR deficiency and high microsatellite instability (MSI-H), and these
are sometimes referred to as Lynch-like tumors. This hypermethylation specifically
inactivates the MLH1 gene through epigenetic silencing. Overall, MSI-H tumors account
for 23-30% of ECs (both sporadic and Lynch-related) (10-13). LS accounts for 2-6% of
ECs overall and 30% of MSI-H ECs are secondary to LS (4, 13, 14)
The clinical relevance of MSI status has recently been recognized, as MSI-H colon
and gastric tumors have shown an overall survival advantage over microsatellite stable
(MSS) tumors (15, 16). In colon cancer, this survival benefit is limited to those patients not
receiving adjuvant chemotherapy (17). Several studies have shown that adjuvant 5fluorouracil is associated with improvement in overall survival in only MSS tumors and
not MSI-H, and demonstrates the use of MSI as a marker of non-response to therapy (17,
18). However, it is not clear whether MSI-H ECs, including Lynch-related ECs,
demonstrate this same survival benefit or whether it may be used as biomarker for therapy
(19-21). Identifying a treatment targeting this molecular subgroup of EC could help to
improve responses in some recurrent and advanced cases.

TREATMENT OF ADVANCED ENDOMETRIAL CANCER
For those patients with advanced and recurrent EC that fail treatment with standard
chemotherapy, response to subsequent chemotherapy is poor, and attempts to identify
promising targeted agents have been limited. Combination chemotherapy in advanced
cases has response rates (RR) of 40-60%, and decreases further to 9-30% if initial therapy
5

is unsuccessful (22-24). Those with recurrent EC that are not candidates for radiation
therapy also have similar responses to combination chemotherapy. In order to improve RR,
attempts to identify drugs that target specific molecular alterations have been made, but
with very limited success. As previously shown and then confirmed in the TCGA, EC has
frequent phosphatase and tensin homolog (PTEN) mutations and aberrant regulation of the
phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR)
signaling pathway. This pathway has been targeted with mTOR inhibitors in those with
recurrent and metastatic EC and shown partial responses of 9-14% and stable disease
ranging from 40-70% (25-27). However, no complete responses have been demonstrated.
Additionally, limited success of less than 15% RR has been seen with other targeted agents,
thus far (28, 29). As of now, no recommended targeted therapies exist for EC despite
attempts to identify subgroups that would benefit from such therapy.
CANCER IMMUNOTHERAPY
Immunotherapy has recently emerged as a promising treatment strategy in multiple
tumor subtypes and could improve treatment outcomes in advanced and recurrent EC.
Tumors demonstrating increased tumor immunogenicity are particularly good candidates
for this type of treatment. The tumor specific somatic mutational rate is thought to correlate
with the number of tumor specific neoantigens produced, based on prediction models (30).
These neoantigens are then recognized by the immune system as non-self and can trigger
an anti-tumoral immune response with immune cell infiltration into these tumors and
cytotoxic T lymphocyte (CTL) activation (30). The ability to then harness and amplify this
anti-tumor immune response is the basis of cancer immunotherapy.

Mounting an Anti-Tumor Immune Response
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Tumor infiltrating lymphocytes (TILs), including CTLs, have been recognized as a
key indicator of anti-tumor immune response. In fact, CTLs are the major effectors of the
adaptive anti-tumor immune response. Naïve CD8+ T cells are transformed into CTLs
through T cell receptor (TCR) recognition of antigen presentation by major
histocompatibility (MHC) class I molecules. This activation also requires co-stimulation
by the T cell associated receptor CD28 binding to either the CD80 or CD86 ligand on the
antigen presenting cell (31). CTLs then direct specific anti-tumor activity through the
release of cytoloytic granules, such as granzyme B and perforin. This was initially
supported in part by the association of TILs and CTLs with improved survival in multiple
tumor types (32-34). While the field of cancer immunotherapy has grown exponentially
in recent years, few studies have focused specifically on endometrial cancer. As a result,
our understanding of mechanisms of immunotherapy must borrow heavily from other
tumor types.
However, CTLs are not the only cells that participate in anti-tumor immune
response. Many different immune cell populations are involved in both the anti-tumor and
immune evasion responses. Natural killer (NK) cells are a component of the innate immune
response and, like CTLs, also have directed cytolytic activity against tumor cells (35).
CD4+ T helper cells, in contrast, contribute to the anti-tumor response by enhancing
activation of CTLs, as well as, NK cells and macrophages (36). Successful cancer
immunotherapy requires tipping the balance to favor anti-tumor response while blocking
mechanisms of tumor evasion. A summary of the immune cells and corresponding
receptors evaluated in this thesis is depicted in table 1.
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Table 1. Common immune cells and immune cell markers seen in the tumor
immune microenvironment.
Immune Cell
T cell
CD8+ T cell

Helper T cell

Natural Killer Cell

Macrophage
Dendritic Cell

Function
Lymphocyte that participates
in cell mediated immunity and
adaptive immune response
T lymphocyte that participates
in the adaptive immune
response with tumor directed
killing after transformation to
CTL
Specific T cell that participates
in the adaptive immune
response through cytokine
release which activates B cells,
T cells, macrophages, and NK
cells
Cytotoxic lymphocyte that
participates in the innate
immune response
Antigen presenting cell and
phagocyte
Antigen presenting cell

Markers
General: CD3

General: CD3, CD8
Activated: Granzyme B
Intraepithelial: CD103

General: CD3, CD4

General: NKp46
Activated: Granzyme B
General: CD68
General: CD11c

Mechanisms of Tumor Evasion
Despite the presence of CTLs in tumors with increased immunogenicity and tumor
directed immune activation, these tumors are still capable of evading the immune response.
Tumor associated macrophages (TAMs) are thought to play a critical role in the
development of immune evasion. These macrophages are induced by cytokines in the
tumor microenvironment (IL-10 and IL-4) to undergo transformation into type II
macrophages (37).

This specific macrophage subset has limited antigen presenting

capacity and instead suppresses T cell function, thus creating a pro-tumorigenic
environment (37).

CD4+ T cells can also be transformed into T regulatory cells which
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have immunosuppressive activity, that is in contrast to the T helper cell function mentioned
previously (38).
Immune evasion is also attributed to upregulation of immune checkpoints on
immune cells that work to dampen the immune response. Normally this pathway helps to
prevent autoimmune tissue destruction; however, the tumor microenvironment hijacks this
immune regulation to prevent ongoing tumor directed immune attack. The most common
immune checkpoints expressed are CTLA-4 (cytotoxic T lymphocyte associated protein 4)
and PD-1 (programmed death 1). Both CTLA-4 and PD-1 function in distinct biological
pathways and demonstrate different patterns of expression (39). Figure 3 summarizes the
CTLA-4 and PD-1 immune cell inhibitor action.

The CTLA-4 receptor is expressed

immediately upon T cell activation, and then competitively binds the T-cell co-stimulatory
signal (CD80 and CD86), to reduce the magnitude of the immune response. PD-1 receptor
expression, in contrast, is delayed as it requires gene transcription. The PD-1 inhibitor
pathway also acts more locally within the tumor microenvironment as the ligand for PD-1
(PD-L1) can be expressed by both tumor and infiltrating immune cells (39). Upregulation
of PD-L1 expression by both the tumor and infiltrating immune cells is another adaptation
for immune evasion (40). In fact, PD-L1 expression has been shown to be upregulated in
tumor cells that are immediately adjacent to TILs and it has been suggested that TILs
induce their own inhibition through cytokine release that result in upregulation of PD-L1
(40).
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Figure 2. Immune checkpoints help to regulate immune responses and can be
utilized by the tumor microenvironment to dampen and inhibit tumor directed
immune responses.
CTLA-4 and PD-1 are commonly expressed immune checkpoints. B27 is expressed by T
cells and binds CD80 and CD86 as a co-stimulatory signal to T cell antigen recognition.
CTLA-4 is also expressed by activated T cells and competitively binds the T cell costimulatory ligands CD80 and CD86 leading to deamplification of the immune response.
Additionally, the PD-1 receptor expression by T cells acts within the tumor
microenvironment to inhibit the immune response. It binds PD-L1 and PD-L2 expressed
by both the tumor and other immune cells.

Expression of Immunotherapy Targets
Expression of PD-L1 differs among tumor types, and remains an area of continued
investigation. A summary of the PD-L1 expression studies discussed below can be found
in Table 2. In a study by Taube et al, PD-L1+ tumors were defined as those with at least
5% tumoral expression and expression was characterized across tumor types. This study
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showed a wide range of expression, with castration-resistant prostate cancers (CRPC)
having no PD-L1+ cases compared to 90% positivity of kidney cancers (41). Additionally,
about 50% of melanoma and non-small cell lung cancer (NSCLC) cases were PD-L1+.
This same study also found positive expression of PD-L1 on infiltrating immune cells in
half of melanomas, NSCLCs, and colorectal cancers (CRC). Another study evaluating
pretreatment PD-L1 expression found PD-L1 expression in several tumor types to be more
common on infiltrating immune cells than on the tumor cells themselves (42). The
percentage of PD-L1+ tumor cells ranged from 1% (CRC) to 24% (NSCLC). In contrast,
the percentage of PD-L1+ immune cells ranged from 12% (pancreatic cancer) to 36%
(melanoma).
Monoclonal antibodies against both CTLA-4 and PD-1, as well as against PD-L1,
have shown efficacy in multiple cancer types, however, the potential value of PD-L1
expression as biomarker for response is still uncertain (43-45). In a study of nivolumab
(anti-PD-1 antibody) across tumor types, objective response was correlated with tumoral
PD-L1 expression but not PD-L1 expression by infiltrating immune cells (41). Treatment
with MPDL3280A (anti-PD-L1 antibody) has also demonstrated objective responses of 1326% among a variety of different malignancies (42). Although the RR alone was not overly
impressive in this study, the majority of responders had durable responses lasting at least
one year. In contrast to nivolumab treatment, response to MPDL3280A was significantly
correlated with PD-L1 expression on immune cells rather than tumoral PD-L1 expression.
Given this early conflicting data that may reflect the differences in the immune
microenvironment among tumor types, the use of PD-L1 expression as a biomarker for
response to immune checkpoint inhibiting agents requires additional investigation.
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Table 2. Immunotherapy literature summary
PD-L1 Studies
Cancer Type
Author(y)
Taube
(2014)

Herbst
(2014)

Melanoma
NSCLC
Colorectal
CRPC

Melanoma
NSCLC
Colorectal
Renal Cell
Head and Neck

Marker
PD-L1+ tumor
or immune
cells (≥5% of
cells)

PD-L1+ tumor
or immune
cells (≥5% of
cells)

Ref
PD-L1 Expression
Tumor Cells
Melanoma (47%)
NSCLC (53%)
Colorectal (13%)
CRPC (0%)
Immune Cells
Melanoma (50%)
NSCLC (53%)
Colorectal (50%)
CRPC (0%)
Tumor Cells
Melanoma (5%)
NSCLC (24%)
Colorectal (1%)
Renal Cell (10%)
Head and Neck (19%)
Immune Cells
Melanoma (36%)
NSCLC (26%)
Colorectal (35%)
Renal Cell (25%)
Head and Neck (28%)

Findings
Treatment with
nivolumab
(anti-PD1)
-PD-L1+ tumor cells
associated with ORR
(p=0.03) and clinical
benefit (p=0.01).
-PD-L1+ immune cells
associated only with
clinical benefit (p=0.04)
Treatment with
MPDL3280A
(anti-PD-L1)
-PD-L1+ immune cells
associated with response
to treatment (p=0.01)
-PD-L1+ tumor cells not
associated with response
(p=0.08)

Abbreviations: NSCLC, non-small cell lung cancer; CRPC, castration-resistant prostate
cancer; overall response rate, ORR

CD8+ T Cell Subpopulations
In addition to the presence of TILs, CTLs, and immune checkpoint expression,
other CD8+ T cell subpopulations have been investigated and associated with improved
survival and tumor immunogenicity. In high grade serous ovarian cancer (HGSOC), the
presence of CD8+ T cells within the tumor epithelium has been associated with improved
prognosis (46). Retention of these CD8+ T cells to the tumor epithelium is thought to be
mediated by expression of CD103 (αE/β7 integrin) on the T cell which binds to E-cadherin
in the tumor epithelium (47). Furthermore, high prevalence of CD8+CD103+ T cells in
HGSOC correlates with enhanced survival (48). This interaction of CD103 with the E12
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cadherin ligand has also been proposed as a mechanism for tumor specific recognition by
CTLs (49).

IMMUNOTHERAPY IN MSI-H TUMORS
Some MSI-H tumor types, have been reported to be more immunogenic and also
demonstrated increased expression of immune checkpoints. MSI-H CRCs have a higher
density of TILs and CTLs and increased immune checkpoint expression compared to MSS
colorectal cancers (50, 51). Specifically, Llosa et al. showed MSI-H CRCs have increased
CTL infiltration and activation within the epithelial component of the tumor, the tumorassociated stroma, and at the invasive front (50). Along with this pro-inflammatory
environment, expression of multiple immune checkpoint markers were also increased in
MSI-H colorectal cancers, including PD-1, PD-L1 , CTLA-4 , LAG-3 (lymphocyteactivation gene 3), and IDO (Indoleamine 2,3-dioxygenase).

It is suggested that the

presence of CTLs and increased immune checkpoint expression in tumors are key
indicators that immunotherapy may have increased efficacy in MSI-H tumors.
Due to these reports of enhanced immunogenicity, the efficacy of immunotherapy
in MSI-H tumors is now being evaluated in clinical studies. Specifically, the observation
of increased immune checkpoint expression in colorectal MSI-H tumors has led to trials of
immune checkpoint blockade. Pembrolizumab, a monoclonal antibody targeting PD-1, was
recently studied in a phase 2 trial of progressive and metastatic MSI-H CRC. This trial
showed improved immune-related objective response rates (encompasses patterns of
response specific to immunotherapy) in MSI-H CRC compared to MSS CRC (52). Of
interest, a third arm of the study included patients with MSI-H non-CRC tumors, including
two women with EC, and also demonstrated improved response to anti-PD-1 therapy. Of
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the two EC patients, one had a complete response and the other a partial response to antiPD-1 therapy. Updates to this study, with the inclusion of additional MSI-H EC patients,
were recently presented at the 2016 Society of Gynecologic Oncology Annual Meeting
(53). Response rates of 56% were seen in the MSI-H EC population (n=9), including one
complete response and four partial responses, and additional studies in MSI-H and MSS
ECs are currently being planned.

IMMUNE MICROENVIRONMENT OF MSI-H ENDOMETRIAL CANCER
While our knowledge of the immune microenvironment in cancer has grown
overall, our understanding in EC has lagged behind. A few studies have evaluated the
relationship of the immune microenvironment and survival in EC. Kondratiev et al,
demonstrated an association with improved overall survival for patients with tumors
containing at least 10 CD8+ T cells at the invasive front (54). Higher numbers of TAMs
are also found in the stroma compared to the tumor epithelium in EC overall, but has not
been associated with tumor stage or disease status (55).
A small number of limited studies have shown conflicting data regarding the
immune microenvironment and immunogenicity of MSI-H EC and these studies have not
addressed Lynch-related cases specifically (56-58). One recent study by Howitt et al
predicted the neoantigen load of MSI-H EC to be 7-fold higher compared MSS EC using
TCGA data (56).

Additionally, this study used immunohistochemistry to characterize

further parameters of the immune microenvironment. However, it is important to note that
the number of cases used in this study was small and immunohistochemistry evaluation
was limited to one high powered field per case. Yet, this limited study found a significantly
higher number of CD3+ and CD8+ TILs in MSI-H and POLE compared to MSS ECs.
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Lastly, PD-L1 expression on immune cells of the MSI-H/POLE tumors was higher than in
MSS, but there was no difference in tumoral PD-L1 expression. Another study by van
Gool et al, also showed higher CD8+ T cell infiltration in both the intraepithelial and
intrastromal regions of MSI-H compared to MSS tumors (59). This same study also
evaluated immune gene expression using TCGA and found increased CD8A and IFNγ
expression in MSI-H tumors, but no significant difference in perforin or granzyme B
expression.
These early studies offer hints that the immune microenvironment of MSI-H ECs
may be similar to that seen in MSI-H CRC with increased immunogenicity and immune
cell infiltration. However, the specifics of the immune environment of MSI-H EC and
how this may differ from MSS EC still remain largely unknown. Therefore, there is a
critical need to understand the immune microenvironment of MSI-H EC to determine if
this subtype is amenable to treatment with immunotherapy. It is also unknown if Lynch
syndrome-related MSI-H (LS MSI-H) ECs have a comparable immune microenvironment
to sporadic MSI-H EC. Our central hypothesis is that MSI-H ECs will have an altered
immune microenvironment compared to MSS ECs, and demonstrate increased immune
checkpoint expression. To address this question we first used TCGA uterine data to
evaluate differences in gene expression and global pathway alterations between MSI-H and
MSS ECs. We then performed immunohistochemistry (IHC) multiplexing with advanced
quantitation methods to further characterize the differences in immunologic markers
between these tumor types.
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Chapter 2: Methods
TCGA ANALYSIS
In collaboration with the Bioinformatics Resource Group at The University of
Texas MD Anderson Cancer Center, TCGA uterine cancer RNA sequencing (RNAseq)
version 2 dataset was used to evaluate gene expression differences between MSI-H and
MSS EC. From this data, 118 MSI-H cases and 160 MSS cases were identified and used
for the analysis. RNAseq read counts were converted into integer values via rounding in
Excel. Genes with a median read count of less than 10 for both groups were filtered out.
This left 15393 genes out of an initial 20531 genes for evaluation. Next, significance
analysis of microarrays (SAM) (Stanford University, CA) was used to detect statistically
significant differences in gene expression between the two groups as two class, unpaired
samples. Only genes with a q value < 0.05 were extracted for further pathway evaluation.
The false discovery rate was accounted for by using the q value that signifies that 5% of
significant results will result in false positives.
Ingenuity Pathway Analysis (IPA) (Qiagen, CA) was then used to investigate
pathway alterations between MSI-H and MSS EC. The differentially expressed genes
obtained from SAM analysis, as described above, were uploaded to IPA to create a Core
Analysis, which was used to investigate differences in canonical pathways in MSI-H versus
MSS tumors.
A more specific TCGA analysis focused on immune-related and inflammatory
genes was later conducted with recently released updated Level 3 uterine cancer data. In
Level 3 expression data, gene and mRNA levels RNAseq data is post normalization and
processed to allow for interpretive analysis (60). This particular analysis evaluated mRNA
16

level differences in a more specific immune and inflammatory gene panel as described by
Lal et al (61). The list of queried genes can be seen in Table 3.
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Table 3. Immune related genes investigated with TCGA uterine data
Gene ID
ACTB
CCL11
CCL2
CCL5
CD247
CD274

CD276
CD3D
CD3E
CD3G
CD4

CD80
CD86
CD8A
CD8B
CTLA4
CX3CL
CXCL10
CXCL9
FOXP3
GNLY
GZMB
HLA-A
HLA-B
HLA-C
HLA-DMA
HLA-DMB
HLA-DOA
HLA-DOB
HLA-DPA1
HLA-DPB1
HLA-DQA1
HLA-DQA2
HLA-DRA
HLA-DRB5
ICAM1
ICOS
IFNG
IL10
IL12RB2
IL17A

Gene Name
Beta actin
Chemokine ligand 11
Chemokine ligand 2
Chemokine ligand 5
CD247 molecule
CD274 molecule
CD276 molecule
CD3d molecule, delta
CD3e molecule, epsilon
CD3g molecule, gamma
CD4 molecule
CD80 molecule
CD86 molecule
CD8a molecule
CD8b molecule
Cytotoxic T-lymphocyte associated protein 4
Chemokine ligand 1
Chemokine ligand 10
Chemokine ligand 9
Forkhead box P3
Granulysin
Granyzme B
Major histocompatibility complex, class I, A
Major histocompatibility complex, class I, B
Major histocompatibility complex, class I, C
Major histocompatibility complex, class II, DM alpha
Major histocompatibility complex, class II, DM beta
Major histocompatibility complex, class II, DO alpha
Major histocompatibility complex, class II, DO beta
Major histocompatibility complex, class II, DP alpha 1
Major histocompatibility complex, class II, DP beta 1
Major histocompatibility complex, class II, DQ alpha 1
Major histocompatibility complex, class II, DQ beta1
Major histocompatibility complex, class II, DR alpha
Major histocompatibility complex, class II, DR beta 5
Intercellular adhesion molecule 1
Inducible T cell co-stimulator
Interferon gamma
Interleukin 10
Interleukin 12 receptor, beta 2
Interleukin 17A
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Gene ID
IL18RAP
IL7R
IRF1
KLRK1
LAG3
MADCAM1
MICB
PDCD1
PDCD1LG2
PROCR
RAET1E
RAET1G
STAT1
STAT3
TBX21
TNFRSF14
TNFSF4
ULBP1
ULPB2
ULPB3
VCAM1
VTCN1

Gene Name
Interleukin 18 receptor accessory protein
Interleukin 7 receptor
Interferon regulatory factor 1
Killer cell lectin-line receptor subfamily K, member 1
Lymphocyte-activation gene 3
Mucosal vascular addressin cell adhesion molecule 1
MHC class I polypeptide-related sequence B
Programmed cell death 1
Programmed cell death 1 ligand 2
Protein C receptor, endothelial
Retinoic acid early transcript 1E
Retinoic acid early transcript 1G
Signal transducer and activator of transcription 1
Signal transducer and activator of transcription 2
T-box 21
Tumor necrosis factor receptor superfamily, member 14
Tumor necrosis factor superfamily, member 4
UL16 binding protein 1
UL16 binding protein 2
UL16 binding protein 3
Vascular cell adhesion molecule 1
V-set domain containing T cell activation inhibitor 1

REAGENTS AND ANTIBODIES
The OpalTM IHC kit (PerkinElmer, MA) was used for fluorescent IHC multiplexing.
The kit included fluorescent tyramide signal amplification (TSA) reagents, amplification
diluent, and DAPI (4',6-diamidino-2-phenylindole).
The following antibodies were used for fluorescent IHC multiplexing: CD3
(1:900, clone SP7, Thermo Scientific, MA), CD4 (1:450, clone 4B12, Thermo Scientific,
MA), CD8 (1:400, clone 4B11, Leica, UK), CD11c (1:1000, clone 5D11, Leica, UK),
Granzyme B (1:300, clone 11F1, Leica, UK), CD103 (1:5000, clone EPR4166, Abcam,
MA), CD68 (1:500, clone KP1, Biogenex, CA), PD-L1 (1:1600, clone E1L3N, Cell
Signaling, MA), and NKp46 (1:4000, clone aa55-104, Lifespan Biosciences, WA).
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Antibody diluent was used for antibody dilution (Invitrogen, CA). 10% normal goat serum
blocking solution was used for background slide blocking (Life Technologies, CA). Citrate
buffer of pH 6.0 was used for antigen retrieval (Poly Scientific, NY). Secondary antimouse or anti-rabbit antibody horseradish peroxidase (HRP) polymer conjugate was used
prior to fluorophore application (Invitrogen, CA). Coverslips were mounted to slides with
aqueous mounting solution (Thermo Scientific, MA)

TUMOR SPECIMENS AND CLINICAL DATA
Endometrial cancer specimens were identified from the gynecologic oncology
archived tumor bank and Lynch syndrome patient registry in accordance with Institutional
Review Board (IRB) protocols. In total, 59 MSI-H EC specimens were identified from
2000-2015.

The majority of cases were from 2012-2015, but this time frame was

expanding to include additional cases from the Lynch syndrome patient registry given the
rarity of these tumors and the need for available primary tumor specimens. These cases
were then matched approximately 1:2 to MSS cases; resulting in identification of 108 MSS
cases. Matching was done according to histology, tumor grade, tumor stage, age at
diagnosis, and body mass index (BMI) at time of diagnosis, as available. Clinical data for
the cohort was abstracted from the medical record. Of the cases identified, nine specimens
were unable to be located.

When the missing specimen was an MSI-H case, its

corresponding matched MSS cases were also filtered out from the dataset. If no MSS cases
were found for any one MSI-H case, the MSI-H case was also removed from the dataset.
Archived formalin-fixed paraffin embedded (FFPE) tumors were cut into 4 micron sections
by the research histology core.
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DETERMINATION OF MSI STATUS AND MMR DEFECT
MSI Testing
MSI status was determined clinically by a method developed by the Molecular
Diagnostic Laboratory at MD Anderson Cancer Center (MDACC) that has been previously
described (62). This data was reported in the medical record and collected retrospectively.
Briefly, MSI testing was performed following extraction of DNA from FFPE tumor and
normal tissue. A polymerase chain reaction (PCR) based method was used for analysis
followed by capillary electrophoretic detection of microsatellite markers.

Seven

microsatellite markers were used in this method. These markers included BAT 25, BAT
26, BAT 40, D2S123, D5S346, D17S250, and TGFBR2.

The number of tumor

microsatellite repeats for each of the markers was compared to normal tissue from the same
case. A tumor was considered to have microsatellite instability if three or more of the
seven markers demonstrated allelic shift.

DNA MMR Deficiency by IHC
The process for identification of DNA MMR deficiency was developed by the
Molecular Diagnostic Laboratory at MDACC as previously described (62), and the
information

was

collected

retrospectively

from

the

pathology

report.

Immunohistochemistry was performed on FFPE tumor blocks to assess expression of
MMR proteins (MLH1, MSH2, MSH6, PMS2). Lack of protein expression of MSH2,
MSH6, or PMS2 in the tumor, by this method, was considered probable Lynch syndrome.
For those with MLH1 loss by IHC, MLH1 promoter methylation was performed. Those
cases showing MLH1 loss by IHC and without MLH1 promoter methylation were
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classified as probable Lynch syndrome. IHC was used to define probable Lynch syndrome
as germline MMR gene mutation testing was not available on all case.
Promoter Methylation
MLH1 promoter methylation status was also determined via a method developed
by the MDACC Molecular Diagnostic Laboratory and collected retrospectively from the
pathology reports in the electronic medical record. Briefly, bisulfate was used to treat
extracted DNA from FFPE samples. This resulted in conversion of cytosine to uracil in
unmethylated cases. PCR amplification of methylated and unmethylated MLH1 promoter
region was performed and these sequences were labeled fluorescently and detected via
capillary electrophoresis as previously described (63).

IMMUNOHISTOCHEMISTRY STAINING
Antibody Optimization
Prior to initiation of IHC multiplexing, each antibody of interest was tested to
determine optimal antibody dilution and antigen retrieval (AR) temperature. A set of serial
dilutions for each antibody was performed based on published IHC data and the
manufactures recommendations to establish the best dilution and AR temperature.

Multiplexing
Multiple panels were required to enable evaluation of nine total markers. Some markers
were repeated on multiple panels to allow for colocalization studies. The individual panels
are described in detail below. Details of the IHC multiplexing protocol follow the
multiplexing panel descriptions.

Multiplexing (6-plex) Panel #1
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For the first IHC multiplexing panel, the following antibodies were used: anti-Granzyme
B for activated CTLs and NK cells, anti-CD8 for CD8+ T cells, anti-NKp46 for NK cells,
anti-CD68 for macrophages, anti-PD-L1 for PD-L1 expressing cells, and DAPI. The order
of antibody application and associated fluorescent TSA reagent was as follows: (1) antiGranzyme B/Cyanine 3 (Cy3), (2) anti-CD8/Fluorescein (FITC), (3) anti-CD68/Cyanine
5.5 (Cy5.5), (4) anti-PD-L1/Cyanine 3.5 (Cy3.5), (5) anti-NKp46/Cyanine 5 (Cy5), and (6)
DAPI. The staining sequence is also represented in Table 4 along with the specific
antibody dilution and manufacturer.

Multiplexing (5-plex) Panel #2
For the second multiplexing panel, a slightly modified set of reagents had been
updated by the manufacturer. The new fluorescent TSA reagents had undergone further
stringent evaluation and optimization by the manufacturer for IHC multiplexing use;
however, all IHC processing steps remained the same. Names of the new fluorophores
(shown below and in Table 4) reflect the excitation wavelength in nanometers (nm). The
following antibodies were used for this multiplexing set: anti-CD3 for all T cells, anti-CD4
for helper T cells, anti-PD-L1 for PD-L1 expressing cells, and anti-CD11c for dendritic
cells. The order of antibody application and associated fluorescent TSA reagent was as
follows: (1) anti-CD3/520 nm, (2) anti-CD4/540 nm, (3) anti-PD-L1/620 nm, (4) antiCDllc/690 nm, and (5) DAPI.

Multiplexing (3-plex) Panel #3
Antibodies for this set included: anti-CD8 for CD8+ T cells and anti-CD103 for
intraepithelial T cells. The order of antibody application and associated fluorescent TSA
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reagent was as follows: (1) anti-CD103/520 nm, (2) anti-CD8/620 nm, and (3) DAPI.
Table 4 contains the specific antibody conditions and staining sequence.

Table 4. Fluorescent IHC multiplexing antibodies and conditions.

Primary Antibody
Multiplexing Panel #1
Granzyme B
CD8
CD68
PD-L1
NKp46
DAPI
Multiplexing Panel #2
CD3

Company

Host

Conc.

AR
Temp
(ᵒC)

TSA

Order

Leica
Leica
Biogenex
Cell
Signaling
Lifespan
Biosciences

mouse
mouse
mouse
rabbit

1:300
1:400
1:500
1:1600

96
96
120
96

Cy3
FITC
Cy5.5
Cy3.5

1
2
3
4

rabbit

1:4000

120

Cy5

5
6

rabbit

1:900

96

520

1

mouse

1:450

96

540

2

rabbit

1:1600

96

620

3

CD11c
mouse 1:1000
96
690
DAPI
Multiplexing Panel #3
CD103
Abcam
rabbit 1:5000
96
520
CD8
Leica
mouse 1:400
96
620
DAPI
Abbreviations: Conc, concentration; AR, antigen retrieval; TSA tyramide signal
amplification.
.

4
5

CD4
PD-L1

Thermo
Scientific
Thermo
Scientific
Cell
Signaling
Leica

1
2
3

Immunohistochemistry Protocol
The OpalTM fluorescent multiplexing kit from Perkin Elmer (Waltham, MA) was
used according to the manufacturer’s protocol as previously described by Stack et al (64).
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Details are given below and a flow chart of the steps can also be seen in Figure 3. Antibody
details including dilutions, manufacturers, and AR conditions are shown in Table 4.

Figure 3. Flow chart of fluorescent IHC multiplexing method.

STEP 1: DEPARAFFINIZATION
Deparaffinization was performed by submerging slides into three successive
containers of xylene for 10 minutes each. A series of ethanol solutions was then used to
rehydrate the tissue as follows: 100% for five minutes, 95% for five minutes, and 70% for
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two minutes. Following rehydration, the slides were washed in distilled water (dH2O) for
two minutes then in Tris-Buffered Saline with 0.05% Tween 20 (TBST) for two minutes.
After deparaffinization, care was taken to ensure slides were kept in light blocking
containers throughout the remaining IHC process to limit unnecessary light exposure.

STEP 2: ANTIGEN RETRIEVAL
Next, AR was carried out by placing the slides in citrate buffer (pH 6.0) and heating
the slides via a decloaking chamber for 15 minutes. The set temperature for AR was
determined

based

on

laboratory

optimization

and

antibody

manufacturers’

recommendations.

STEP 3: WASH
After heating was completed, the slides were removed from the decloaking
chamber and cooled for 20-30 minutes to room temperature. The slides were then washed
in dH2O for two minutes followed by TBST for two minutes. For the NKp46 antibody, an
additional wash of 1% hydrogen peroxide for 10 minutes followed by a TBST was for two
minutes was used to decrease endogenous peroxidase activity. This step was not required
for any of the other antibodies.

STEP 4: BLOCKING
Slides were then removed from the wash solution. Excess liquid was wiped from
the slides and the tissue was demarcated using a hydrophobic barrier pen. Sufficient 10%
normal goat serum (Life Technologies, CA) blocking solution was applied to cover the
tissue (75-100 microliters (μL)) and slides were incubated in a humidified chamber.
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STEP 5: PRIMARY ANTIBODY
After 30 minutes, the blocking solution was removed from the slides and primary
antibody was applied to the tissue. Again, sufficient diluted antibody solution (75-100 μL)
was used to cover the tissue. Slides incubated with the primary antibody in a humidified
chamber at 4ᵒC overnight. For the anti-CD103 antibody, the slides were incubated at room
temperature for 30 minutes in a humidified chamber before proceeding with washing as
described below. All other antibodies used the overnight incubation procedure.
After overnight incubation (approximately 16 hours), primary antibody was
removed from the slides. The slides were then washed in TBST with agitation and at room
temperature for two minutes. This wash process was repeated three times.

STEP 6: SECONDARY HRP CONJUGATE
Slides were wiped of excess liquid and 100 μL of diluted secondary HRP conjugate
(Invitrogen, CA) was applied to the tissue. Depending on the host species of the primary
antibody, either mouse or rabbit secondary HRP conjugate was used.

Slides were

incubated in a humidified chamber at room temperature for 10 minutes. The slides were
again washed three times in TBST with agitation at room temperature for two minutes.

STEP 7: TSA APPLICATION
The fluorophore labeled TSA reagent was first resuspended in 150 μL of dimethyl
sulfoxide (DMSO) and then diluted 1:50 in 1X Amplification Diluent (Perkin Elmer, MA)
to produce the working TSA solution. Slides were wiped of excess liquid and 75-100 μL
of TSA working solution (Perkin Elmer, MA) was applied to the tissue. The slides were
incubated in a humidified chamber at room temperature with the TSA solution for 10
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minutes. The slides were again washed in TBST for two minutes at room temperature three
times. A different fluorophore labeled TSA solution was used for each antibody.

STEP 8: ANTIGEN RETRIEVAL/HEATING
Slides were again heated in citrate buffer of pH 6.0 for 15 minutes in a decloaking
chamber. Following heating, the slides were left to cool to room temperature for 20-30
minutes in the citrate buffer. The slides were then washed with dH20 for two minutes,
followed by TBST for two minutes at room temperature. The specific temperature was
determined by the conditions needed for AR of the next antibody to be applied. For the
last heating step in the multiplexing sequence, 96ᵒC was used.
After step 8, the process was repeated beginning at step 3 for each subsequent
antibody used. After the final antibody and fluorophore labeled TSA solution was applied,
the process proceeded to step 9.

STEP 9: DAPI
DAPI solution from the OpalTM fluorescent multiplexing kit (PerkinElmer, MA)
was then applied. This solution was diluted two drops in one mL of TBST prior to
application. 100 μL of the diluted DAPI solution was applied to the tissues and incubated
in a humidified chamber at room temperature for five minutes. DAPI was then removed
and the slides were washed in dH20 for two minutes. A drop of aqueous mounting solution
(Thermo Scientific, CA) was applied to the slides for cover slip mounting. The slides were
stored in a dark container at 4ᵒC.

Control Slides
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Individual fluorophore control slides were prepared for each antibody and
associated fluorophore labeled TSA reagent in order to create a spectral library and to
determine imaging exposure times for each fluorophore. This was accomplished using
IHC steps 1-8 as described above. Similarly, a DAPI only slide was stained using the
described IHC steps 1-3. DAPI was then applied as described in step 9. Lastly, an
unstained slide of uterine tissue was deparaffinized and heated as above and mounted to be
used for determination of autoflourescence during the imaging analysis process.

IMAGING AND DATA ANALYSIS
The imaging and inForm® analysis portion of the project was performed with
assistance from the MDACC Flow Cytometry and Cellular Imaging Facility.
Imaging
Due to the multiple antibodies and multiple fluorophores used for several markers
on each slide, unique imaging was required. This multispectral imaging was accomplished
with the Vectra® 2 automated system (PerkinElmer, MA). This system allows for the
capture of tissue images at multiple wavelengths and is able to analyze multiple markers,
or antibodies, on a single slide. Analysis of multiple markers on a single slide also enables
colocalization studies.
Initial low power images at 4X were obtained for all tissue on each slide. Up to 30
high power field images were then randomly captured at 20X through automation by the
Vectra® system. These fields were captured based on highest density of tumor cells in the
images. A series of sample EC multiplex images from the data set were used to define
areas of tumor, stroma, and normal tissue that was then applied to create a pattern
recognition algorithm for high power field acquisition. For the multiplexing sets, four
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filters were used to capture images (DAPI, Cy3, FITC, and Cy5). Exposure times were
determined for each of the filters using a representative individually stained slide, and
subsequently used for acquisition of all images.

inForm® Analysis
Once images were obtained, the inForm® system version 2.1.5430.24864 was used
to create a spectral library of each of the fluorophores. Images from the single fluorophore
slides were used for this library. This allowed for unmixing of the individual fluorophores,
and confirmed unique staining for each of the antibodies.
This same system was also used to identify tissue regions of interest and to score
positive cellular tagging of the antibodies of interest. A series of multiplex images were
randomly selected to provide a sample set of images to define areas of tumor epithelium,
tumor associated stroma, myometrium and blank space. This sample set of images was then
used to train the inForm® system in pattern recognition of these different tissue segments.
The training algorithm also included DAPI and each spectral component, specific to the
multiplex staining panel, to create the tissue segmentation algorithm that was applied to all
images. The system was subsequently able to classify the pixels within the training set
with 85-94% accuracy.
Next, DAPI staining was used to identify nuclei within each of the tissue
compartments, and to obtain total cell counts with in each of the compartments. The DAPI
staining was also used as a reference to determine cellular cytoplasm and membrane
segmentation based on the inForm® algorithm. Thresholds and scoring for positively
staining cells for each of the antibodies were determined through manual examination of
each antibody among the EC multiplex training images. This examination included
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identifying a fluorescent pixel intensity that accurately identified positive staining cells
across the training set within the cellular compartment (cytoplasm or membrane) unique to
each of the antibodies. Signal thresholds were determined using average fluorescent pixel
density for each of the fluorophores and corresponding antibodies. Thresholds, along with
cellular compartment of interest, are as follows:


Multiplexing Panel #1: Granzyme B/Cy3 - membrane (score >3), CD8/FITC membrane (score >2), PD-L1/Cy3.5 - cytoplasm (score >5), NKp46/Cy5 membrane (score >1), and CD68/Cy5.5 – cytoplasm (score >1).



Multiplexing Panel #2: CD3/520 nm – membrane (score >0.83), CD4/540 nm membrane (score >0.33), PD-L1/620 nm - cytoplasm (score >2.5), and CDllc/690
nm - membrane (score >0.2).



Multiplexing Panel #3: CD103/520 nm – membrane (score >2.0) and CD8/620 nm
- membrane (score >4.5).
For each antibody, signal greater than the determined threshold was considered

positive staining.
An inForm® algorithm was then run based on the previously defined tissue
segmentation, identification of individual cells and corresponding cellular compartments,
and the scoring system for each of the antibodies of interest. The generated composite
images were reviewed manually, and the reviewer was blinded to MSI status during this
review. In the manual review, images that were determined to have inaccurate tissue
segmentation were added to the training set of images to improve segmentation accuracy.
However due to the wide variation of tissue architecture, 100% accuracy was unable to be
obtained and those images that appeared to have gross segmentation inaccuracy were
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excluded from the analysis. Overall, there were on average 16 images analyzed per
specimen (range 1-35).

A small subset of slides required reimagining due to poor

identification of tissue and tumor by the automated system, and in these cases, more than
30 images were allowed in repeat image capture. This accounts for the increased number
of images in two cases with greater than 30 images.
Some cases were not included in the overall analysis due to problems with tissue
quality or imaging. This occurred because of tissue degradation (likely due to multiple
rounds of heating from the multiplexing process), lack of tumor cells present in that section,
or lack of tumor images captured by the automated system from inaccurate tissue
segmentation for image acquisition. If the removed case was MSI-H, the corresponding
MSS matched pairs were also removed. Additionally, if a MSS case that was removed
resulted in no matched cases for a MSI-H case, the MSI-H case was also removed from the
analysis.
The number of positive staining cells for each of the antibodies was determined per
millimeter squared (mm2) within the tumor epithelium and tumor associated stroma for
each of the cases using code written in SAS version 9.2 (Cary, NC) by collaborator Gary
Chisholm (Programmer/Analysis, Department of Gynecologic Oncology and Reproductive
Medicine).

STATISTICAL ANALYSIS
Statistical analysis was performed using Stata version 14.1 (College Station, TX).
The Mann-Whitney and Kruskal-Wallis tests were used to compare demographic data
between the groups as indicated. For overall comparison of immune cellular markers
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between MSI-H and matched MSS cases, the nonparametric Mann-Whitney test was used.
The Mann-Whitney test was also used for comparison of sporadic MSI-H and matched
MSS cases, as well as, MSI-H Lynch cases compared to MSS matches. A p value of < 0.05
was used to signify statistical significance. Box plots were also created to compare
differences among mRNA levels, positive staining cell counts, and percent positive
staining cells. The upper border of the box represents the third quartile, the lower border
the first quartile, and the line the median. The whiskers are defined using the Tukey box
plot method where they represent 1.5 times the upper and lower interquartile range.
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Chapter 3: Results
TCGA ANALYSIS
Using TCGA uterine cancer RNAseq data, global gene expression was compared
for 118 MSI-H endometrioid endometrial cancers and 160 microsatellite stable tumors.
Analysis of the differential gene expression revealed 2148 upregulated and 2645
downregulated genes in MSI-H tumors compared to MSS tumors. Further examination of
global pathway alterations using IPA demonstrated significant activation of the granzyme
B signaling pathway in MSI-H compared to MSS tumors (p<0.01), but not in other
immune- or inflammatory-related pathways. Genes in the granzyme B pathway include
but are not limited to: granzyme B, perforin, caspase 3, caspase 8, caspase 9, apoptotic
peptidase activating factor, DNA fragmentation factor, endonuclease G, and cytochrome
c. Upon cytotoxic cell activation, the granzyme B pathway triggers cellular apoptosis of
target cells and increased pathway activation suggests increased CTL activity in MSI-H
tumors.
A panel of specific immune- and inflammatory-related genes was also compared
using TCGA RNAseq data. Of the 64 genes evaluated, mRNA levels in MSI-H tumors
were significantly elevated for 11 genes (p<0.01). These genes included multiple T cell
effector (CD8a, ICOS, MICB, ULBP1), T cell attractant chemokine (CXCL9), immune
checkpoint (LAG3), NK cell effector (ULBP2, ULBP3), immune cytokine (IFNG),
regulatory T cell (FOXP3), and beta actin (ACTB) genes. A subset of the significant
mRNA comparisons between MSI-H and MSS EC is represented in Figure 4. MSI-H
tumors also had significantly decreased mRNA levels of an eosinophil chemotactic
cytokine gene (CCL11) (p<0.01).
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Figure 4. MSI-H ECs demonstrate increased expression of multiple T cell effector
genes compared to MSS EC.
Analysis of RNAseq TCGA uterine cancer data comparing log2 mRNA level differences
in MSI-H and MSS EC for (A) FOXP3, (B) CD8A, (C) IFNG, (D) LAG3, (E) CXCL9,
and (F) ICOS represented by box plots.

SPECIMENS
Analysis of EC cases was conducted using specimens from the gynecologic
oncology archived tumor bank and Lynch syndrome patient registry. In total, 59 MSI-H
cases were identified and matched approximately 1:2 to 108 MSS cases. Of the MSI-H
cases, 20 were found to have IHC defects in MMR genes consistent with probable Lynch
syndrome and this group was used for the LS MSI-H sub-analysis. 37 MSI-H cases
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demonstrated sporadic promoter methylation of MLH1 and were used for the sporadic
MSI-H sub-analysis. One case had loss of MSH2 and MSH6 on IHC, but no germline
deleterious mutations of DNA MMR genes. One case had unknown specific protein loss,
but was positive for microsatellite instability with allelic shift in 5 of 7 microsatellite
markers. These last two cases were included only in the overall MSI-H versus MSS
analysis. Among the 20 LS MSI-H cases, IHC loss of primary MMR proteins were as
follows: 3 (15.0%) in MLH1, 14 (70.0%) in MSH2, 3 (15.0%) in MSH6, and no cases
showed loss of PMS2 or EPCAM.

DEMOGRAPHICS
There were no significant differences in characteristics used for case matching
(histology, age at diagnosis, BMI, stage, and grade) as shown in Table 5. Some data could
not be obtained for a small number of cases in the MSI-H cohort, almost exclusively Lynch
Syndrome EC cases. The majority of these cases were obtained from a Lynch syndrome
patient registry where specimens included those collected from outside institutions, which
had more limited associated clinical information. Of these, 11 cases were missing details
of depth of myometrial invasion and 12 were missing LVSI information. As comparison
of depth of invasion and LVSI were not primary objectives, and these cases were not
excluded from the cohort. In addition, 2 cases had unknown grade (both LS MSI-H) and 5
had unknown stage (All LS MSI-H). However, these cases were matched according to the
data available and were included in the analysis given the limited number of cases of the
LS MSI-H subtype.
The majority of cases were stage IA in both groups (MSI-H 59.3% vs MSS 66.7%;
p=0.80) with about 13% representing more advanced stage III or IV cases (MSI-H 13.6%
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vs MSS 13.0%; p = 0.80). The majority of cases were grade 2 in each of the groups (MSIH 69.5% vs MSS 75.9%; p=0.63), and more aggressive grade 3 cases made up 17.0% in
the MSI-H and 13.0% in the MSS cohort. As most cases were stage IA, only 25.4% had
myometrial invasion equal to or greater than 50% in the MSI-H and 26.9% in the MSS
cases. Lastly, there was a significant difference in lymphovascular space invasion (LVSI)
between the two groups with more MSS cases having LVSI present (67.6%) than that seen
in the MSI-H (39.0%) cases (p=0.02).

Table 5. Baseline patient characteristics by MSI-H and MSS status.

Mean Age (y)
Mean BMI (kg/m2)
Histology, N (%)
Endometrioid
Undifferentiated
Mixed
Stage, N (%)
IA
IB
II
III/IV
Unknown
Grade, N (%)
1
2
3
Unknown
Depth of Myometrial
Invasion, N (%)
No invasion
< 50%
≥ 50%
Unknown
LVSI, N (%)
Present
Absent
Unknown

MSI-H (N=59)
63.0
34.3

MSS (N=108)
59.5
36.5

55 (93.2)
1 (1.7)
3 (5.1)

106 (98.2)
1 (0.9)
1 (0.9)

35 (59.3)
8 (13.6)
3 (5.1)
8 (13.6)
5 (8.5)

72 (66.7)
17 (15.7)
5 (4.6)
14 (13.0)
--

P value
0.84
0.19
0.60

0.80

0.63
6 (10.2)
41 (69.5)
10 (17.0)
2 (3.4)

12 (11.1)
82 (75.9)
14 (13.0)
-0.46

8 (13.6)
25 (42.4)
15 (25.4)
11 (18.6)

24 (22.2)
55 (50.9)
29 (26.9)
-0.02*

23 (39.0)
24 (40.7)
12 (20.3)
37

73 (67.6)
33 (30.6)
2 (1.9)

Abbreviations: BMI, body mass index; kg/m2, kilograms per meter squared; LVSI,
lymphovascular space invasion
IMMUNE MICROENVIRONMENT OF MSI-H ENDOMETRIAL CANCER COMPARED TO MSS
TUMORS

The immune microenvironment in MSI-H versus MSS EC was examined using
three fluorescent IHC multiplexing panels. The first panel evaluated positive staining of
CD8 (CD8+ T cells), granzyme B (activated CTLs or NK cells), CD68 (macrophages), PDL1 (immune checkpoint ligand), and NKp46 (NK cells). Staining with the NKp46 antibody
was difficult to optimize and ultimately resulted in nonspecific staining. As a result, this
marker could not be analyzed. The second panel measured positive staining for CD3
(general T cell marker), CD4 (CD4+ T cells), PD-L1 (immune checkpoint ligand), and
CD11c (dendritic cell marker). Finally, the third panel evaluated positive staining of
CD103 (intraepithelial T cell or dendritic cell marker) and CD8 (CD8+ T cells).
Representative images for each of the multiplexing panels are demonstrated in Figure 5.
Markers repeated in multiple panels (PD-L1 and CD8) demonstrated substantial variation
in overall total positive cell counts in subsequent multiplexing panels. However, as noted
in Methods, batch effects for multiplex staining (due to differences in conditions between
panels) make it necessary for comparison of these markers to only be performed within a
multiplexing batch. PD-L1+ staining showed a 1.2-1.4 fold difference in the stroma and a
1.4-2 fold difference in the tumor epithelial compartment. While CD8+ staining had a 1.21.3 fold difference in the stroma and a 1.5-2.1 fold difference in the tumor epithelial
compartment. Additionally, the counts in the tumor epithelial compartment may be less
reliable due to the low overall positive cell counts which are reflected in the wider variation
of fold difference within the tumor epithelial compartment.
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Figure 5. Fluorescent IHC multiplexing panel images.
(A) Representative image of IHC multiplexing panel 1 including: CD8 (green), Granzyme
B (red), CD68 (orange), PD-L1 (magenta), and DAPI (blue). (B) Representative image of
IHC multiplexing panel 2 including: CD3 (green), PD-L1 (red), CD4 (magenta), CD11c
(white), and DAPI (blue). (C) Representative image of IHC multiplexing panel 3 including:
CD 103 (green), CD8 (red), and DAPI (blue). S indicates peritumoral stroma; G indicates
tumor glandular epithelium.
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Details of the number of positively stained cells per marker within both the stromal
and tumor epithelial compartments for the entire cohort are shown in Table 6 to enable
comparison of the relative abundance of positive staining across different tissue
compartments and markers (within each individual multiplex panel, as indicated on the
table). Among all MSI-H tumors, the mean number of granzyme B+, PD-L1+, and CD4+
staining cells were significantly higher within the tumor associated stroma. As other studies
have looked at the percentage of PD-L1+ cells, this was also assessed in our cohort to allow
for comparison across studies. The percentage of PD-L1+ staining stromal cells was also
significantly increased in the MSI-H cases (59.2% vs 49.0%; p<0.01), but not in the tumor
epithelium (5.4% vs 3.8%; p=0.26) when compared to MSS EC (Figure 6A and 6B). There
was no statistically significant difference seen in the mean number of stromal cells staining
positive for CD3, CD8, CD103, CD68, or CD11c between MSI-H and MSS tumors.
In evaluating the tumor epithelial compartment, the mean number of granzyme B+
staining cells in the MSI-H group was significantly higher, while the mean number of
CD68+ staining cells within the tumor epithelial compartment was significantly lower in
the MSI-H versus MSS cases. There was no significant difference seen in mean number
of cells staining positive for CD3, CD4, CD8, CD103, CD11c, or PD-L1 between MSI-H
and MSS tumors in the tumor epithelial compartment.

Table 6. Comparison of positive staining cell counts between MSI-H and MSS ECs

Marker

All MSI-H EC

MSS EC

Mean No of positive
cells/mm2 (range)

Mean No of positive
cells/mm2 (range)

Stromal Compartment
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P value

CD81
50.7 (0-180.1)
39.4 (0-342.6)
0.06
1
Granzyme B
114.9 (0.1-440.4)
75.8 (0-657.2)
<0.01*
1
CD68
29.1 (0-156.6)
22.9 (0-127.9)
0.86
1
PD-L1
291.6 (107.6-434.2) 240.5 (28.6-408.3)
<0.01*
2
CD3
89.5 (0.3-282.2)
69.7 (3.4-179.0)
0.05
2
CD4
25.4 (0-82.4)
17.8 (0.2-76.1)
0.02*
2
CD11c
22.1 (0-133.9)
17.4 (0-133.3)
0.49
3
CD103
7.9 (0-107.4)
4.8 (0-128.8)
0.30
Tumor Epithelial
Compartment
CD81
7.9 (0-53.5)
5.1 (0-38.4)
0.07
Granzyme B1
38.9 (0-391.0)
32.6 (0-433.8)
<0.01*
CD681
1.8 (0-8.5)
2.8 (0-19.2)
0.03*
1
PD-L1
21.3 (0-243.8)
15.4 (0-214.2)
0.29
2
CD3
51.5 (0.1-349.6)
37.9 (1.0-236.1)
0.23
2
CD4
25.6 (0-255.8)
17.1 (0-130.4)
0.31
2
CD11c
8.9 (0-83.1)
11.1 (0-87.7)
0.27
3
CD103
23.5 (0-111.6)
17.7 (0-92.5)
0.48
1
2
3
Multiplex panel 1; Multiplex panel 2; Multiplex panel 3; *p<0.05. Abbreviations:
MSI-H, high microsatellite instability; MSS, microsatellite stable; EC endometrial
cancer.

Figure 6. MSI-H ECs show increased stromal PD-L1 expression compared to MSS
ECs.
(A) Box plot representing the percentage of PD-L1+ cells within the peritumoral stroma
compartment of MSI-H vs MSS EC. (B) Box plot of the percentage of PD-L1+ cells
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within the tumor intraepithelial compartment of MSI-H vs MSS EC. The center line of
the box plot indicates the median. *p value <0.05. Abbreviations: MSI-H, high
microsatellite instability; MSS, microsatellite stable.

Comparison of marker colocalization in each tissue compartment is shown in Table
7. Co-staining of CD8+ and granzyme B+ cells was analyzed to assess the number of
activated CTLs within the two groups. In all MSI-H tumors, there were significantly more
activated CTLs in both the stromal and in the tumor epithelial compartments. There was
also a significant increase seen in colocalization of PD-L1+ and CD11c+ staining cells (PDL1+ dendritic cells) among the stroma in all MSI-H versus MSS EC, but not in the tumor
epithelial compartment. Stromal colocalization staining for activated CTLs and PD-L1+
dendritic cells is shown in Figures 7A and 7C. Colocalization of CD3+ and CD4+ staining
cells, denoting T helper cells, demonstrated a significant increase in mean number of cells
between all MSI-H and MSS in the stroma, but not within the tumor epithelial
compartment. Lastly, no difference was seen in colocalization of CD103+ and CD8+
positive cells (intraepithelial CD8+ cells) or of PD-L1+ and CD68+ staining cells (PD-L1+
macrophages) in either of the compartments in all MSI-H versus MSS EC. Stromal PDL1+ macrophages are represented in Figure 7B.

Table 7. Comparison of co-staining positive cell counts between MSI-H and MSS
ECs
Marker
Colocalization in Stromal
Compartment
CD81/Granzyme B1
PD-L11/CD681

All MSI-H EC

All MSS EC

Mean No of positive
cells/mm2 (range)

Mean No of positive
cells/mm2 (range)

45.6 (0.7-179.1)
25.1 (0-148.4)

28.0 (0-228.4)
15.6 (0-93.8)
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P value

<0.01*
0.49

CD32/CD42
24.9 (0-82.3)
17.4 (0.2-75.7)
0.02*
2
2
PD-L1 /CD11c
6.7 (0-66.3)
4.3 (0-97.9)
0.01*
3
3
CD8 /CD103
5.22 (0-83.0)
2.92 (0-94.0)
0.26
Colocalization in Tumor
Epithelial Compartment
CD81/Granzyme B1
5.7 (0-53.5)
2.3 (0-11.6)
0.03*
1
1
PD-L1 /CD68
0.5 (0-5.5)
0.2 (0-1.8)
0.74
2
2
CD3 /CD4
25.0 (0-255.8)
16.8 (0-130.3)
0.25
2
2
PD-L1 /CD11c
0.4 (0-11.3)
0.2 (0-1.6)
0.14
3
3
CD8 /CD103
1.7 (0-43.3)
0.51 (0-1.5)
0.20
1
2
3
Multiplex panel 1; Multiplex panel 2; Multiplex panel 3; *p<0.05. Abbreviations:
MSI-H, high microsatellite instability; MSS, microsatellite stable; EC, endometrial
cancer.
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Figure 7. MSI-H ECs have increased stromal activated CTLs and PD-L1+ dendritic
cells compared to MSS ECs.
(A) Box plots demonstrating the number of positive cells per mm2 of activated CTLs (costaining of CD8 and granzyme B), (B) PD-L1+ macrophages (co-staining of PD-L1 and
CD68), and (C) PD-L1+ dendritic cells (co-staining of CD11c and PD-L1) in the
peritumoral stroma. The center box plot line indicates the median positive cell count. *p
value <0.05. Abbreviations: CTL, cytotoxic T lymphocyte; MSS, microsatellite stable;
MSI-H, high microsatellite instability.

SPORADIC MSI-H ENDOMETRIAL CANCER
A secondary sub-analysis was then performed to assess differences in the immune
microenvironment of sporadic MSI-H EC compared to MSS tumors (excluding LS MSIH cases). This analysis included only MSI-H tumors with MLH1 promoter methylation
compared to matched MSS tumors. The overall mean values for each marker are depicted
in Table 8. Within this subgroup, the number of granzyme B+, CD3+, and CD4+ staining
cells within both the tumor associated stroma and the tumor epithelial compartments was
higher among the sporadic MSI-H versus MSS cases. This was in comparison to only
increased stromal and tumor epithelial granzyme B+ staining cells and stromal CD4+
staining cells in all MSI-H versus MSS cases. The percentage of PD-L1+ staining cells
(61.1% vs 45.3%; p<0.01) was significantly higher in the stromal compartment for
sporadic MSI-H versus MSS cases like that seen in all MSI-H cases (Fig 8A), as well as
within the tumor epithelial compartment (sporadic MSI-H 6.3% vs MSS 2.3%; p=0.03)
(Fig 8B). As seen in all MSI-H versus MSS cases, there was no difference in the mean
number of positive staining cells within the stroma for CD8, CD68, CD11c, or CD103 in
sporadic MSI-H compared to MSS EC. In the tumor epithelial compartment, mean positive
staining cell counts for CD8, CD68, CD11c, or CD103 were also not significantly different
between sporadic MSI-H versus MSS cases.
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Table 8. Comparison of positive staining cell counts between sporadic MSI-H and
MSS ECs.
Marker
Stromal Compartment
CD81
GranzymeB1
CD681
PD-L11
CD32
CD42
CD11c2
CD1033
Tumor Epithelial
Compartment
CD81
Granzyme B1
CD681
PD-L11
CD32
CD42
CD11c2
CD1033

Sporadic MSI-H EC

MSS EC

Mean No of positive
cells/mm2 (range)

Mean No of positive
cells/mm2 (range)

P value

36.9 (0-133.7)
107.4 (12.3-377.9)
36.6 (0.5-156.6)
297.3 (112.7-433.9)
88.1 (11.7-233.7)
26.6 (2.7-73.4)
22.8 (0-133.9)
7.2 (0-107.4)

45.3 (0-342.6)
84.1 (0-657.2)
20.9 (0-127.9)
225.9 (28.6-408.3)
65.9 (3.4-179.0)
16.5 (0.2-76.1)
16.5 (0-133.3)
5.7 (0-128.8)

0.62
0.02*
0.25
<0.01*
0.03*
<0.01*
0.21
0.40

5.9 (0.1-20.1)
43.5 (0-391.0)
2.4 (0-8.5)
25.0 (0.2-243.8)
56.5 (4.0-349.6)
29.7 (0.9-255.8)
9.9 (0-83.1)
24.8 (0-111.6)

5.5 (0-38.4)
35.2 (0-433.8)
2.8 (0-19.2)
10.0 (0-68.3)
33.3 (1.4-181.7)
14.5 (0.1-117.4)
11.6 (0-87.7)
18.4 (0-92.5)

0.30
<0.01*
1.0
0.02*
0.04*
0.04*
0.63
0.43
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1

Multiplex panel 1; 2Multiplex panel 2; 3Multiplex panel 3; *p<0.05. Abbreviations:
MSI-H, high microsatellite instability; MSS, microsatellite stable; EC, endometrial
cancer.

Figure 8. Sporadic MSI-H ECs show increased stromal and tumor epithelial PD-L1
expression compared to MSS ECs.
(A) Box plot representing the percentage of PD-L1+ cells within the peritumoral stroma
compartment of sporadic MSI-H vs MSS EC. (B) Box plot of the percentage of PD-L1+
cells within the tumor intraepithelial compartment of sporadic MSI-H vs MSS EC. The
center line of each box plot represents the median. *p value <0.05. Abbreviations: MSIH, high microsatellite instability; MSS, microsatellite stable.

Table 9 compares positive co-staining cell counts within the stromal and tumor
epithelial compartments. Sporadic MSI-H cases demonstrated an increase in stromal PDL1+ dendritic cells (co-staining of PD-L1 and CD11c). This finding was similar to that
seen in the analysis of all MSI-H versus MSS cases. There was no difference in PDL1+dendritic cells in the tumor epithelial compartment of sporadic MSI-H compared to
MSS cases. There was also an increase in PD-L1+ macrophages (co-staining PD-L1 and
CD68) in the stroma of sporadic MSI-H versus MSS cases which was not seen in the
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analysis of all MSI-H versus MSS cases, but no differences in the intraepithelial
compartment.

Additionally, T helper cells (co-staining of CD3 and CD4) were

significantly increased in both the stromal and tumor epithelial compartments in sporadic
MSI-H versus MSS cases in contrast to only in the stroma of all MSI-H versus MSS cases.
No difference was seen in activated CTLs (co-staining of CD8 and granzyme B) in either
the stroma or tumor epithelial compartment in contrast to that seen in all MSI-H compared
to MSS EC. There was also no difference seen in intraepithelial CD8+ cells (co-staining of
CD103 and CD8) in either the stromal or tumor epithelial compartments like that in all
MSI-H versus MSS EC. Box plot comparisons of stromal CTLs, PD-L1+ macrophages,
and PD-L1+ dendritic cells are shown in Figures 9A, 9B, and 9C.

Table 9. Comparison of co-staining positive cell counts between sporadic MSI-H
and MSS ECs.
Marker

Sporadic MSI-H EC

MSS EC

Mean No of positive
cells/mm2 (range)

Mean No of positive
cells/mm2 (range)

P value

Colocalization in the Stromal
Compartment
CD81/Granzyme B1
32.4 (0.7-98.3)
31.0 (0-228.4)
0.41
1
1
PD-L1 /CD68
31.3 (0-148.4)
13.4 (0-93.8)
0.04*
2
2
CD3 /CD4
26.0 (2.4-73.1)
16.0 (0.2-75.7)
0.01*
2
2
PD-L1 /CD11c
6.5 (0-66.3)
3.7 (0-97.9)
0.01*
3
3
CD8 /CD103
4.3 (0-72.1)
3.4 (0-13.3)
0.36
Colocalization in the Tumor
Epithelial Compartment
CD81/Granzyme B1
3.8 (0-18.4)
2.5 (0-11.6)
0.15
1
1
PD-L1 /CD68
0.7 (0-5.5)
0.2 (0-1.8)
0.05
2
2
CD3 /CD4
29.1 (0.9-255.8)
14.1 (0.1-117.2)
0.03*
2
2
PD-L1 /CD11c
0.2 (0-1.1)
0.2 (0-1.6)
0.34
3
3
CD8 /CD103
0.8 (0-8.3)
0.5 (0-13.3)
0.30
1
2
3
Multiplex panel 1; Multiplex panel 2; Multiplex panel 3; *p<0.05. Abbreviations:
MSI-H, high microsatellite instability; MSS, microsatellite stable: EC, endometrial
cancer.
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Figure 9. Sporadic MSI-H ECs have increased stromal PD-L1+ macrophages and
PD-L1+ dendritic cells compared to MSS ECs.
(A) Box plots demonstrating the number of positive cells per mm2 of activated CTLs (costaining of CD8 and granzyme B), (B) PD-L1+ macrophages (co-staining of PD-L1 and
CD68), and (C) PD-L1+ dendritic cells (co-staining of CD11c and PD-L1) in the
peritumoral stroma. The center box plot line indicates the median positive cell count. *p
value <0.05. Abbreviations: CTL, cytotoxic T lymphocyte; MSS, microsatellite stable;
MSI-H, high microsatellite instability.

LYNCH-RELATED MSI-H ENDOMETRIAL CANCER
Lastly, evaluation of the differences in the immune microenvironment in LS MSIH EC compared to matched MSS cases was conducted, and mean positive staining cell
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counts are depicted below in Table 10. LS MSI-H EC demonstrated a significantly higher
mean number of granzyme B+ staining cells within the tumor associated stroma compared
to MSS tumors as was also seen in all MSI-H and sporadic MSI-H analyses. In contrast to
that seen in the all MSI-H and sporadic MSI-H versus MSS analyses, there were also a
significantly higher mean number of CD8+ staining cells in both the stromal and tumor
epithelial compartments among LS MSI-H versus MSS tumors. The mean number of
CD68+ staining cells was found to be significantly reduced in both the stromal and tumor
epithelial compartments in LS MSI-H cases compared to MSS EC, in contrast to all MSIH versus MSS analyses where CD68+ positive staining cells were only reduced in the tumor
epithelial compartment.
There was no significant difference observed in the mean number of granzyme B+
staining cells within the tumor epithelial compartment between LS MSI-H and MSS EC in
contrast to the other analyses. Mean positive staining cell counts in the stroma between LS
MSI-H and MSS tumors showed no difference in CD3, CD4, CD103, or CD11c as
compared to the increased CD3+ and CD4+ staining cell counts in sporadic MSI-H versus
MSS EC. In the tumor epithelial compartment, mean positive staining cells counts were
not significantly different between LS MSI-H and MSS EC for CD3, CD4, CD11c, or
CD103. This finding was similar to that seen in the analyses of all MSI-H compared to
matched MSS EC. There was no difference in mean PD-L1+ staining cells between the LS
MSI-H and MSS EC in either the stromal or tumor epithelial compartments which was
different from the increased PD-L1+ staining among stromal cells in both sporadic MSI-H
and all MSI-H versus MSS analyses. There was also no difference in mean percentage of
PD-L1+ staining cells in the stroma (LS MSI-H 56.2% vs MSS 58.1%; p=0.92) and tumor
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epithelial (LS MSI-H 3.5% vs MSS 7.2%; p=0.15) compartments in LS MSI-H versus MSS
EC (Figure 10A and 10B).

Table 10. Comparison of positive staining cell counts between LS MSI-H and MSS
ECs.
Marker

LS MSI-H EC

MSS EC

Mean No of positive
cells/mm2 (range)

Mean No of positive
cells/mm2 (range)

P value

Stromal Compartment
CD81
78.4 (6.6-180.1)
25.9 (0-86.4)
<0.01*
1
Granzyme B
150.7 (12.1-440.4)
58.3 (2.3-323.9)
0.01*
1
CD68
14.6 (0-58.0)
28.3 (0-82.7)
0.03*
1
PD-L1
281.5 (107.6-434.2) 274.0 (118.6-387.6)
0.54
2
CD3
94.0 (0.3-282.2)
80.9 (17.2-167.4)
0.82
2
CD4
21.7 (0-82.4)
21.8 (0.7-63.1)
1.0
2
CD11c
19.6 (0-92.1)
20.1 (0-75.5)
0.46
3
CD103
9.44 (0-85.1)
2.61 (0-34.3)
0.81
Tumor Epithelial
Compartment
CD81
12.0 (0.6-53.5)
4.1 (0.1-14.0)
0.04*
1
Granzyme B
46.6 (0.6-248.8)
28.3 (0.1-402.6)
0.10
CD681
0.7 (0-5.7)
3.1 (0.2-11.8)
<0.01*
PD-L11
15.6 (0-71.4)
29.2 (0.2-214.2)
0.15
2
CD3
36.0 (0.1-120.0)
51.3 (1.0-236.1)
0.42
2
CD4
12.6 (0-92.1)
24.9 (0-130.4)
0.23
2
CD11c
5.9 (0-24.7)
9.8 (0-39.0)
0.12
3
CD103
19.1 (0-73.9)
16.5 (0-50.8)
0.79
1
2
3
Multiplex panel 1; Multiplex panel 2; Multiplex panel 3; *p<0.05. Abbreviations: LS
MSI-H, Lynch syndrome high microsatellite instability; MSS, microsatellite stable; EC
endometrial cancer.
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Figure 10. LS MSI-H ECs show no difference in stromal or tumoral PD-L1
expression compared to MSS ECs.
(A) Box plot representing the percentage of PD-L1+ cells within the peritumoral stroma
compartment of LS MSI-H vs MSS EC. (B) Box plot of the percentage of PD-L1+ cells
within the tumor intraepithelial compartment of LS MSI-H vs MSS EC. The center line
of each box plot represents the median. Abbreviations: LS MSI-H, Lynch syndrome
high microsatellite instability; MSS, microsatellite stable.
Colocalization staining is represented in Table 11. There was a significantly higher
mean number of activated CTLs (co-staining with CD8 and granzyme B) in LS MSI-H
versus MSS cases with higher stromal and tumor epithelial positive cells as was seen in all
MSI-H compared to matched MSS EC. Within the tumoral epithelial compartment, there
was a significant decrease in colocalization of PD-L1 and CD68 (PD-L1+ macrophages) in
LS MSI-H compared to MSS EC, but no difference within the stroma. Lastly, there was
no difference seen in colocalization of PD-L1 and CD11c (PD-L1+ dendritic cells), CD3
and CD4 (T helper cells), or CD103 and CD8 (CD8+ intraepithelial cells) in either of the
compartments between LS MSI-H and MSS EC. This was in contrast to the increased
stromal PD-L1+ dendritic cells seen in the comparison of all MSI-H and sporadic MSI-H
cases to matched MSS
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Table 11. Comparison of co-staining positive cell counts between LS MSI-H and
MSS ECs.
Marker

LS MSI-H EC

MSS EC

Mean No of positive
cells/mm2 (range)

Mean No of positive
cells/mm2 (range)

P value

Colocalization in the Stromal
Compartment
CD81/Granzyme B1
68.4 (6.1-179.1)
21.4 (0.2-74.4)
0.01*
1
1
PD-L1 /CD68
4.1 (0-15.0)
7.5 (0-21.0)
0.06
2
2
CD3 /CD4
21.7 (0-82.3)
21.5 (0.7-61.8)
0.98
2
2
PD-L1 /CD11c
7.4 (0-26.8)
6.2 (0-48.9)
0.56
3
3
CD8 /CD103
7.45 (0-83.0)
1.68 (0-33.7)
0.73
Colocalization in the Tumor
Epithelial Compartment
CD81/Granzyme B1
9.1 (0.3-53.5)
2.0 (0-6.9)
0.03*
1
1
PD-L1 /CD68
0.8 (0-5.0)
2.5 (0-12.0)
0.02*
CD32/CD42
12.5 (0-47.5)
24.8 (0-130.3)
0.22
2
2
PD-L1 /CD11c
1.2 (0-11.3)
0.1 (0-0.6)
0.23
3
3
CD8 /CD103
4.0 (0-43.3)
0.6 (0-11.2)
0.58
1
2
3
Multiplex panel 1; Multiplex panel 2; Multiplex panel 3; *p<0.05. Abbreviations: LS
MSI-H, Lynch syndrome high microsatellite instability; MSS, microsatellite stable; EC,
endometrial cancer.
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Figure 11. LS MSI-H ECs have increased activated CTLs compared to MSS ECs.
(A) Box plots demonstrating the number of positive cells per mm2 of activated CTLs (costaining of CD8 and granzyme B), (B) PD-L1+ macrophages (co-staining of PD-L1 and
CD68), and (C) PD-L1+ dendritic cells (co-staining of CD11c and PD-L1) in the
peritumoral stroma. The center box plot line indicates the median positive cell count. *p
value <0.05. Abbreviations: CTL, cytotoxic T lymphocyte; MSS, microsatellite stable;
LS MSI-H, Lynch syndrome high microsatellite instability.
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Chapter 4: Discussion
As our understanding of the molecular and clinical heterogeneity of EC has grown,
it is clear that a variety of therapeutic approaches will be required for successful outcomes
both as upfront treatment and for recurrent/advanced cases. While clinical trials of
molecularly targeted single agents have shown disappointing results in EC,
immunotherapy has emerged as a promising therapeutic option in multiple tumor types that
previously had limited treatment options and poor overall prognosis (65, 66). This
immunologic tumor-directed response is thought to be activated by tumor-specific
neoantigens that correlate with somatic mutational load and infiltration of CD8+ CTLs.
This thesis sought to provide a detailed analysis of the immune microenvironment of MSIH EC and potential implications for response to immunotherapy. Previous studies of the
immune microenvironment in EC were limited and had not fully investigated sporadic
MSI-H and LS MSI-H cases (56, 59). These studies are critical to identifying therapeutic
targets for advanced and recurrent EC given the limited treatment options should patients
fail standard chemotherapy. Currently, there are no targeted therapies in clinical use for
molecular subsets of EC, but early studies of the immune microenvironment of MSI-H EC
have suggested that these tumors may be more immunogenic and thus responsive to
immunotherapy (56, 59).
Analysis of TCGA uterine data suggested increased CTL activity in MSI-H
compared to MSS EC. This was shown through increased activation of the granzyme B
pathway in MSI-H EC overall which leads to targeted cell apoptosis through CTL directed
cytolytic activity.

Additionally, the more specific immune-related TCGA analysis

identified upregulated mRNA levels of several T cell effector genes (CD8a, MICB,
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CXCL9, and ICOS), that further supports at least an initial enhanced anti-tumoral response
in MSI-H versus MSS EC.
The comprehensive examination of the immune cell populations in MSI-H and
MSS EC identified differences in the immune microenvironment of these two subtypes.
MSI-H tumors had increased granzyme B+ staining cells and CTL activation within both
the tumor epithelium and tumor associated stroma and increased Helper T cells in the
stroma.

This suggests an immune mediated anti-tumor response in this subset of ECs.

Stromal PD-L1 expression was also significantly increased in MSI-H EC and reflects
immune response exhaustion and suppression. Among all MSI-H cases, however, there
was no significant difference in other T cell populations (CD3+, CD8+, and CD103+
intraepithelial T cells), CD68+ macrophages or CD11c+ dendritic cells when compared to
MSS tumors.
Sub-analysis of sporadic MSI-H EC also demonstrated a difference in the immune
microenvironment compared to MSS tumors. Sporadic MSI-H EC had increased CD3+,
CD4+, and granzyme B+ cells in the stroma and tumor epithelium compared to MSS tumors
reflecting an immune related response in these tumors. Additionally, increased stromal
and tumoral PD-L1 expression along with increased stromal PD-L1+ macrophages and PDL1+ dendritic cells was seen compared to MSS EC.
Lastly, sub-analysis of LS MSI-H showed increased CTL activation compared to
MSS EC. This was demonstrated by increased stromal CD8+ cells, granzyme B+ cells, and
activated CTLs in LS MI-H versus MSS EC. CD8+ cells and activated CTLs were also
increased in the tumor epithelial compartment in LS MSI-H versus MSS EC. In contrast
to the all MSI-H and sporadic MSI-H versus MSS analyses, LS MSI-H cases demonstrated
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no difference in PD-L1+ staining in the stromal or tumor epithelial compartment compared
to MSS EC. Additionally, CD68+ cells were significantly reduced in the stromal and tumor
epithelial compartments of LS MSI-H versus MSS tumors.
Analysis of both immune cell markers and markers of immune response activity is
needed to provide a complete view of the immune microenvironment. Previously, studies
in MSI-H and POLE ECs have found elevated levels of CD3+ and CD8+ infiltrating
lymphocytes suggesting increased tumor immunogenicity in these subtypes (56, 59).
Additionally, other studies have shown that CD103 expression enhances retention of T
cells in the tumor epithelium and is also associated with polarization of cytolytic granules
(47, 67). This then primes the T cell for cytotoxic activity once antigen recognition has
occurred. Although our study did not show a difference in CD8+ or CD103+ cells between
all MSI-H and MSS EC, there was a significant difference in granzyme B+ cells and
activated CTLs as demonstrated by colocalization of CD8 and granzyme B. This provides
further evidence of a more active immune microenvironment in MSI-H EC, and suggests
that the CTLs that are present are activated and capable of mounting an anti-tumor immune
response. Inevitability, however, such activation is followed by exhaustion and inhibition
via immune checkpoint expression, such as PD-L1.
While an overall characterization of immune cell types is informative, an
understanding of expression patterns for specific markers is also important for improved
immunotherapy studies and clinical trials. PD-L1 expression on tumor versus stromal cells
may have important implications for therapeutic response to anti-PD-L1 therapies, but
expression varies among tumor types (41, 42). Our study found low overall expression of
tumoral PD-L1+ cells and no difference in expression between all MSI-H and MSS EC.
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However, we did find elevated levels of stromal cell PD-L1 expression with a significant
increase in both all MSI-H and sporadic MSI-H versus matched MSS EC. Additionally,
sporadic MSI-H also showed increased tumoral PD-L1 expression versus MSS EC.
Although many studies have focused on tumor PD-L1 expression and its ability to predict
response to anti-PD-1 and anti-PD-L1 therapy, its role as a biomarker remains unclear (41,
42). Further evaluation of PD-L1 expression among tumor types prior to treatment is
needed, as well as, in responders and non-responders following immune checkpoint
blockade therapy.
To further define the stromal PD-L1 expressing cells in our study, colocalization
analysis of PD-L1 with both CD68 (macrophages) and CD11c (dendritic cells) was
conducted. Overall there was no difference between all MSI-H and MSS EC in the number
of CD68 or CD11c cells positive alone, but there was an increase in those co-expressing
PD-L1 and CD11c (PD-L1+ dendritic cells). The sporadic MSI-H sub-analysis also
showed an elevated number of PD-L1+ macrophages and PD-L1+ dendritic cells compared
to MSS EC, suggesting that both macrophages and dendritic cells may be key regulators
of immune inhibition in the sporadic MSI-H EC microenvironment. This finding along
with the correlation of PD-L1 expression on CD163 myeloid cells in MSI-H colorectal
cancers, seen in other studies, suggests an alternate mechanism for immune response
inhibition in these tumors from direct tumor cell suppression. Other immune checkpoints
are also likely contributing to immune suppression, as suggested by increased LAG-3 gene
mRNA levels in MSI-H tumors from our TCGA analysis. As therapies targeting these other
immune cell populations and immune checkpoints (i.e. TAMs and LAG-3) are becoming
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available, additional studies are needed to further characterize these populations in MSI-H
EC in order to expand treatment options.
Looking more closely at the sub-analysis of sporadic MSI-H EC, sporadic MSI-H
tumors demonstrate both increased markers of immune cell infiltration and immune
suppression compared to MSS EC. MSI-H EC had increased CD3+, CD4+, and PD-L1+
staining cell populations in both the stromal and tumor epithelial compartments compared
to matched MSS tumors. From these findings we can conclude that sporadic MSI-H,
compared to MSS ECs, have increased immune cell infiltration and subsequent suppression
of the immune response through checkpoint activation. These findings most closely mirror
those found in the other MSI-H EC and colorectal microenvironment studies previously
discussed, and suggest that sporadic MSI-H EC would respond favorably to single agent
immune checkpoint blockade.
The role of immune checkpoint expression in LS MSI-H ECs, on the other hand, is
less clear. Sub-analysis of LS MSI-H EC demonstrated increased CD8+ and active CTLs
in both the stroma and tumor epithelial compartments, but no difference in PD-L1
expression when compared to matched MSS cases. Similar to sporadic MSI-H versus MSS
EC analysis, LS MSI-H EC also appears to promote an immunogenic microenvironment,
but the same PD-L1 checkpoint expression was not seen. We can speculate that other
immune checkpoints such as CTLA-4, TIM-3 (T cell immunoglobulin and mucin-domain
containing-3) or LAG-3 may play a larger role in this subtype. Further studies specifically
evaluating the expression of CTLA-4, TIM-3, LAG-3, and other immune checkpoints
markers are needed to more clearly define immune checkpoint activity in these tumors, and
to draw a more complete picture of the LS MSI-H immune microenvironment in EC.
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Additionally, in some instances single agent immune checkpoint blockade is
insufficient to overcome immune inhibition while combination therapy is able to target
multiple immune checkpoint pathways (65, 68). In melanoma, combination anti-CTLA-4
and anti-PD-1 therapy has shown particular benefit in patients with PD-L1 negative tumors
(65). Additionally, synergistic effects of combination immune checkpoint blocking agents
have been shown in preclinical trials of combination anti-TIM-3 or anti-LAG-3 with antiPD-1. Such combination therapies may provide more clinical benefit in LS MSI-H EC than
single agent immune checkpoint blockade (69, 70). Along with this, consideration of
combination immunotherapy and traditional cytotoxic agents may further improve
response rates. In non-small cell lung cancer, preliminary phase I studies have shown
activity and tolerability of combination of immune checkpoint blockade and
chemotherapeutic agents (71, 72). This may be of particular importance in LS MSI-H EC
where there is suggestion that the immune checkpoint expression is less robust. Here
alternative immune checkpoint blockade or combination therapies are likely required.
Overall, this study provides new insight into the immune microenvironment related
to MSI status in EC. It is the largest cohort assessing the immune microenvironment of
MSI-H EC and the first to specifically investigate LS MSI-H EC cases. This large cohort
was also matched to reduce confounding factors that influence immune cell populations
and immune marker status (matched according to histology, grade, stage, age at diagnosis
and BMI). There may, however, be some decrease in the overall differences of positive
cell counts seen between MSI-H and MSS EC as MSS EC cases had higher rates of LVSI
which is a known risk factor for disease recurrence. In addition to this unique sample set,
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immune microenvironment characterization was more powerful due to the use of
multiplexed IHC coupled with digital imaging for quantitation and colocalization analysis.
This study overcomes limitations observed in previous immune cell studies in EC,
such as evaluation of limited high powered fields and inconsistent quantitation and scoring
strategies. Vectra imaging and inForm software provided computer automated random
high power field selection and counting of positively stained cells, allowing for an
objective and uniform assessment of immunohistochemical staining.

Traditionally,

staining quantification by IHC is limited to a few high powered fields that are chosen based
on areas of representative staining, and it is difficult to control for interpreter bias. In
contrast, the true random selection of up to 30 HPFs in our study provides a more global
reflection of the immune microenvironment of the samples, and is less likely to be biased
by areas of sparse or concentrated staining.

Furthermore, the identification of positive

staining thresholds and computer quantification reduces inter- and intra-observer
variability of positive cell counting.
It is also important to recognize the limitations of this new imaging and quantitation
methodology. Despite improving the objectivity of IHC analysis in our study, some
subjective measures are still used in the process of developing these methods, such as
determination of positive signal thresholds and lack of 100% accuracy in identifying tumor
and stroma compartments. Importantly, these limitations in the analysis would not be
skewed towards any one group and would not change the trends in the immune markers
seen. While multiplexing IHC panels empower analysis of multiple markers on a single
tissue section, this methodology is particularly sensitive to batch effects and must be
considered in both study design and analysis. Comparisons of markers between groups
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must be confined to staining within a single batch (single panel), as demonstrated by the
differences in PD-L1 and CD8 staining intensity among the panels. There are multiple
reasons that may contribute to difference in staining intensity. Different temperatures used
in antigen retrieval for the unique antibodies used in the different panels can impact antigen
retrieval. Specifically, elevated temperatures used in multiplexing panel 1 may have
enhanced antigen retrieval and staining intensity resulting in the increased intensity of PDL1 staining in panel 1. Additionally, the IHC staining and processing of slides in this
method is conducted manually. As such, there is likely to be some slight variation between
timing across batches in any one of the 8 steps, in particular the 5 steps that are repeated
up to 4 times. This points to the importance of ensuring that all slides are stained together
and that comparisons can only be made within one batch. In this specific case, the
consistent trend in stromal PD-L1 expression does support a difference in PD-L1
expression between MSI-H and MSS EC.
This study could be further improved by adding analysis of POLE mutation status
as this EC molecular subtype has been shown to have an even more immunogenic
microenvironment than MSI-H EC (56, 59). As these tumors tend to be MSS, the counts
of immune cells and immune markers in the MSS group may have been elevated and
resulted in a smaller overall difference in positive cell counts between the two groups.
Despite this, stratifying patients by MSI status for consideration of immune checkpoint
blockade is the most clinically feasible as patients with POLE mutations are much less
likely to recur.
In considering next steps to further evaluate efficacy of immunotherapy in the MSIH EC patient population, a phase 2 study evaluating response rates to immune checkpoint
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blockade in patients with MSI-H and MSS EC is needed. A potential study design was
created in collaboration Dr. Amir Jazaeri and is depicted in Figure 12.

Briefly, such a

study would include patients with advanced or recurrent EC that have failed initial standard
chemotherapy. Patients with MSI-H tumors would make up the first arm and those with
MSS tumors the second arm. Treatment would begin with a single agent anti-PD-1 or antiPD-L1 therapy. Anti- CTLA-4 treatment would then be added for those that progressed or
did not respond to single agent therapy, as combination anti-CTLA-4 and anti-PD-1 has
previously shown improved responses to single agent therapy in other tumor types (65).
This adaptive approach would help to maximize benefit from immune checkpoint blockade
in the entire cohort by adding a second agent for non-responders, while also identifying
those who do respond to a single agent to minimize adverse effects from an unnecessary
second agent.
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Figure 12. Proposed phase 2 trial to evaluate the role of immune checkpoint
blockade in advanced and recurrent EC.
Abbreviations: EC, endometrial cancer; MSI-H, high microsatellite instability; MSS;
microsatellite stable; SD, stable disease.
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Chapter 5: Conclusions

In summary, this thesis shows that MSI-H ECs have an altered immune
microenvironment compared to MSS ECs. Specifically, MSI-H EC compared to MSS EC
demonstrated increased activation of the granzyme B pathway and elevated levels of
activated CTLs. This increased cytolytic activity indicates an immune related anti-tumor
response in MSI-H EC. Additionally, increased stromal PD-L1 expression was seen in all
MSI-H EC versus MSS and suggests a shift to a pro-tumorigenic microenvironment and
suppression of the immune response. As our understanding of the spectrum of patients
benefiting from immunotherapy and immune checkpoint blockade widens, these therapies
may prove to be advantageous in EC patients. Our finding of increased activated CTLs and
stromal PD-L1 expression in MSI-H ECs identifies patients with this molecular subset of
tumors as candidates for treatment with immunotherapy.
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